NRSN
NeuroSense·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NRSN
Neurosense Therapeutics Ltd.
A company that developing treatments for severe neurodegenerative diseases
Biological Technology
02/13/2017
12/09/2021
NASDAQ Stock Exchange
15
12-31
Common stock
11 HaMenofim Street, Building B, Herzliya 4672562 Israel
--
NeuroSense Therapeutics Ltd. was incorporated in Israel on February 13, 2017. The company is a clinical-stage biotechnology company focused on discovering and developing treatments for patients with neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead therapeutic candidate, PrimeC, is a novel sustained-release oral formulation consisting of a fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. PrimeC is designed to treat ALS by regulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which are hallmarks of ALS pathology.
Company Financials
EPS
NRSN has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.04, meeting expectations. The chart below visualizes how NRSN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
